Carolina Reduzzi, Assistant Professor of Cancer Biology Research in Medicine and Director of Cristofanilli CTC laboratory at Weill Cornell Medicine, shared a post on LinkedIn:
“CTCs: from prognosis to treatment selection?
In our analysis of the PACE study, published on CCR AACR Journals Baseline CTC enumeration (≥5 CTCs, stage IV-aggressive) identifies patients with extended PFS from fulvestrant+palbociclib (F+P) or F+P+avelumab vs F alone.
The impact was confirmed also after adjusting for clinical and mutational status.”
Title: Circulating tumor cells dynamics after CDK4/6 inhibitor for hormone-receptor positive metastatic breast cancer: a biomarker analysis from the PACE phase II study.
Authors: Lorenzo Gerratana, Carolina Reduzzi, Yue Ren, Rinath Jeselsohn, Reshma L. Mahtani, Cynthia X. Ma, Angela DeMichele, Jane L. Meisel, Kathy Miller, Yara Abdou, Elizabeth C. Riley, Rubina Qamar, Priyanka Sharma, Sonya A. Reid, Naomi Ko, Yuan Liu, Eric Gauthier, Harold J. Burstein, Michelle DeMeo, Sara M. Tolaney, Meredith M. Regan, Massimo Cristofanilli, Erica L. Mayer
Read the Full Article.
